Disc Medicine appointed Lisa Amaya Price as CHRO with a 37,500-share option and 29,000 RSUs to build its commercialization organization. Bitopertin’s NDA was accepted under accelerated priority review after CNPV designation and $791 million cash runway supports Phase 2 data readouts due H2 2026.